$NOV.N-CH News
Last published 8mo ago
- 8mo agoNOV.N-CHGILDNovartis, Genentech file suit alleging illegal importation of prescription drugCNBCNovartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.
- 1y agoNOV.N-CHNovartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'CNBCNovartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.
- 1y agoNOV.N-CHSwiss pharma giant Novartis bets on a breast cancer blockbuster as sales riseCNBCSales of breast cancer drug Kisqali grew 100% in the U.S. in the three months to June.
- 2y agoAZN-GBBMYLLYNVS+4This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&ACNBCTargeted radiopharmaceuticals, which deliver radiation directly into tumors, has caught the eye of big pharma.
- 3y agoNOV.N-CHNovartis unit Sandoz set to start trading after completing spinoffCNBCNovartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.
- 3y agoBMYJNJMRKAZN-GB+5Drugmakers opt in to Medicare drug price negotiations – here's what happens nextCNBCThe lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.
- 3y agoNVSNOV.N-CHRHHBFNovartis stock jumps after drugmaker raises full-year guidance, launches $15 billion buybackCNBCNovartis raised its guidance and announced the buybacks as the Swiss drugmaker reported second-quarter earnings, which topped Wall Street's expectations.
- 3y agoNVSNOV.N-CHPKGMMM+6Stocks making the biggest moves premarket: Novartis, First Republic, 3M and moreCNBC3M said it would cut about 6,000 positions to focus on high-growth markets, such as automotive electrification and home improvement.
- 3y agoNOV.N-CHNVSRadioligand therapy, a 'game-changer' for cancer treatment, forces manufacturers to race against a ticking clockCNBCRadioligand therapy is a 'game -hanger' for cancer treatment, but it forces manufacturers to race against a ticking clock.
- 3y agoNOV.N-CHTop pharma CEO says Covid likely to become endemic, urges investment in pandemic preparednessCNBCNovartis CEO Vas Narasimhan made clear that world leaders must learn from the coronavirus crisis to be in a better place for future pandemics.
- 4y agoTWTRTSLASBUXJPM+9Stocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and moreCNBCThe stocks making the biggest moves in premarket trading include Twitter, Tesla, Starbucks, and more.
- 4y agoADBEABNBHOODWOOF+9Stocks making the biggest moves midday: Adobe, Airbnb, AT&T, Robinhood, Novartis and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 4y agoDALACNREGNLEN+8Stocks making the biggest moves premarket: Delta Air Lines, Accenture, Regeneron and othersCNBCThese are the stocks posting the largest moves before the bell.
- 5y agoORCLPFENOV.N-CHElizabeth Holmes case draws closer to end as government says it will rest next weekCNBCInvestor Alan Eisenman took the stand in the criminal fraud trial of Elizabeth Holmes, his investment in Theranos underpins one of the wire fraud counts.
- 5y agoNOV.N-CHPFE22UA-DE5CV-DENovartis CEO says Covid-related doctor visit delays likely impacting cancer diagnosis ratesCNBCNovartis CEO Vasant Narasimhan told CNBC there are now lower rates of diagnoses due to reduced hospital visits during the coronavirus pandemic.
- 5y agoNOV.N-CHNovartis CEO says future pandemics are bound to happen. Here's how to prepare for the next oneCNBCThe CEO of Swiss pharmaceutical giant Novartis on Wednesday outlined how policymakers and the healthcare industry can improve pandemic preparedness.
- 5y agoELMDPGTNDKNG+15Stocks making the biggest moves in the premarket: Estee Lauder, Meredith Corp., DraftKings & moreCNBCThe stocks making the biggest moves in premarket trading include Estee Lauder, Meredith Corp., DraftKings, and more.
- 5y agoNOV.N-CHThe UK's National Health Service just approved a drug that costs nearly $2.5 million a doseCNBCThe innovative gene therapy called "Zolgensma" does not come cheap, with a reported list price of £1.79 million ($2.48 million) per dose.
- 5y agoOKTAMRVLVRMBJ+12Stocks making the biggest moves in the premarket: Okta, Marvell Technology, Vroom & moreCNBCThe stocks making the biggest moves in premarket trading include Okta, Marvell Technology, Vroom, and more.
- 5y agoMRNAPFENOV.N-CHBNTXModerna said to seek FDA clearance to increase doses per vial to alleviate manufacturing bottleneckCNBCModerna asked the FDA to allow it to put more doses of its Covid-19 vaccine in each vial to alleviate a bottleneck in manufacturing.
- 5y agoAXPGEAPOJNJ+14Stocks making the biggest moves in the premarket: GE, Apollo Global, J&J, GameStop & moreCNBCThe stocks making the biggest moves in premarket trading include GE, Apollo Global, J&J, GameStop, and more.
- 5y agoTLRYAPHA-CAPENUAL+13Stocks making the biggest moves in the premarket: Tilray, Aphria, Penumbra, Moderna & moreCNBCThe stocks making the biggest moves in premarket trading include Tilray, Aphria, Penumbra, Moderna, and more